Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response

Abstract

Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.